Hikma’s Olafsson Sees Benefits From Broad Injectables Portfolio
Lessens Impact As Products In Shortage Return To US Market
Shortages are still driving growth in the US injectables market for Hikma, but the breadth of the firm’s portfolio means it has less exposure to the pressures of in-shortage products returning to market, according to CEO Siggi Olafsson.
